What Insulet's latest 10-Q says: 5 signals
Insulet filed its latest 10-Q with the SEC on Aug 5, 2026. It discusses capacity constraint, capex increase and market expansion.
Public (PODD)Medical Equipment Manufacturing1,001 to 5,000 employeesinsulet.comLinkedIn
- Filed
- Aug 5, 2026
- Filings
- 2
- Signals
- 16
10-Q · latest 10
What Insulet's 10-Q filings say
- SEC EDGAR
10-Q
Filed · 5 signals
CapEx up 84% to $56.8M for new Costa Rica plant and manufacturing expansion.
Capital expenditures increased significantly to support global manufacturing expansion, including initial investment in a new Costa Rica plant.
$56.8M
Capital expenditures for the six months ended June 30, 2026
Insulet commits $77.4M to NXP USA for semiconductor chips to secure supply chain.
To proactively mitigate supply chain risk for critical components, Insulet has entered a large purchase agreement for semiconductor chips.
$77.4M
Purchase commitment for semi-conductor chips
NXP USA, Inc.
- SEC EDGAR
10-Q
Filed · 11 signals
Insulet appoints Michael Panos as new CFO in March 2026, replacing Ana Chadwick.
The company finalized a separation agreement with former CFO Ana Chadwick in February 2026 and issued an offer letter to new CFO Michael Panos in March 2026.
Insulet signs $96.9M purchase commitment with NXP for semiconductor chips.
The company has entered into a new agreement to secure approximately $96.9 million in semiconductor chips, a critical component.
$96.9M
Purchase commitment for semi-conductor chips
NXP USA, Inc.
Insulet records $11.7M charge for voluntary medical device correction in March 2026
The company incurred an $11.7 million cost for estimated warranties related to a voluntary medical device correction.
$11.7M
Estimated warranty costs for voluntary medical device correction
Insulet boosts capex for global manufacturing expansion and new Costa Rica plant
Capital expenditures nearly doubled YoY to $24.3M in Q1 2026, driven by investments in new machinery, equipment, and the initial build-out of a new manufacturing facility in Costa Rica.
$24.3M
Q1 2026 Capital Expenditures
International Omnipod revenue surges 28.5% to $223.1 million in Q1 2026.
The company is experiencing rapid growth in international markets, which now represent nearly 30% of total revenue.
$223.1M
Q1 2026 International Omnipod revenue
28.5%
Year-over-year growth in International Omnipod revenue
Top three distributors now account for 38% of Insulet's total revenue
Revenue is concentrated with three distributors representing 14%, 13%, and 11% of total revenue respectively in Q1 2026.
38%
Portion of total revenue from top three distributors (14% + 13% + 11%)
Insulet boosts R&D spending by $30.1M YoY to enhance its Omnipod platform.
Research and development expenses increased significantly due to increased headcount and project costs focused on product innovation for the Omnipod platform.
$30.1M
Year-over-year increase in Q1 R&D spending
Insulet settles trade secret lawsuit with competitor EOFlow Co. Ltd.
After a jury found that EOFlow misappropriated trade secrets, Insulet entered into a settlement and license agreement in April 2025.
$100M
Upfront payment received from EOFlow settlement
EOFlow Co. Ltd.
Showing 10 of 16 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Insulet earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Announced meaningful increase in CapEx for manufacturing expansionLeadership is accelerating investments to increase capacity at its manufacturing facilities to support a strong growth trajectory. This creates opportunities for vendors in construction, industrial automation, equipment, and supply chain management. | |
| Appointed new CFO, COO, and created new Chief Growth Officer roleA major C-suite refresh includes a new CFO (Flavia Pease), a promoted COO (Eric Benjamin), and a new CGO (Manoj Raghunandanan), signaling potential shifts in financial, operational, and growth strategies that often trigger vendor reviews. | |
| Integrating AI and cloud-based tools to scale service operationsThe company is actively integrating AI and cloud technologies to streamline and efficiently scale its customer service operations. This points to active projects and budget for AI/ML platforms, cloud infrastructure, and customer service automation solutions. | |
| Expanding sales, commercial, and customer experience teamsThe company is actively hiring to expand its sales force and customer-facing teams to drive market penetration and support a growing customer base. This signals needs for HR tech, recruiting services, sales enablement tools, and CRM solutions. | |
| Actively addressing friction in the prior authorization submission processLeadership identified the prior authorization process as a key barrier to patient access and is implementing targeted programs to ease submissions. This creates an opportunity for vendors specializing in healthcare workflow automation and patient access solutions. | |
| Achieved record new customer starts globally, with Type 2 doublingThe company is experiencing unprecedented customer acquisition, particularly in the U.S. Type 2 market where new starts doubled year-over-year. This rapid scaling requires robust systems for customer onboarding, support, data management, and engagement. |
Signal API · MCP
Track Insulet with the Signal API
One POST /v1/companies/enrich call with insulet.com returns Insulet 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"insulet.com","signal_types":["sec-10q"],"limit":20}'Same industry
10-Q at related companies
Questions about Insulet 10-Q
When did Insulet file its latest 10-Q?
What did Insulet disclose in its latest 10-Q?
What did Insulet say on its recent earnings calls?
Where can I read Insulet's 10-Q filing?
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .